Drs. Anne Tsao of MD Anderson Cancer Center, Patrick Forde of Johns Hopkins, and James Stevenson of the Cleveland Clinic join Mary Hesdorffer to discuss a new clinical trial, Dream3r, a phase 3 study into the efficacy of combination chemotherapy with immunotherapy as first line treatment for mesothelioma.
Our sponsors
MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Maune Raichle Hartley French & Mudd, LLC (MRHFM); Belluck & Fox; Bristol Myers Squibb; Novocure; Merck; The Gori Law Firm; Early Lucarelli Sweeney & Meisenkothen.
